Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
In This IssueAbstract
Open Access

In this issueSystematic ReviewOriginal Articles

Saudi Medical Journal June 2022, 43 (6) 539;
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Systematic Review

Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients. Meta-analysis of available literature

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Mortality in patients using prophylactic anticoagulants versus therapeutic anticoagulants.

Waheed et al compare a total of 7120 patients recruited in 11 studies the mortality associated with the intensity of anticoagulation in patients admitted with covid-19. Using prophylactic anticoagulants was associated with a 42% reduction in mortality compared to therapeutic anticoagulants. A total of 6069 patients were recruited in 4 studies in which 2 studies significantly favored prophylactic anticoagulants in terms of reducing mortality. Cumulatively, the meta-analysis showed that using prophylactic anticoagulants was associated with a 5% reduction in mortality but without any statistical significance. Meta-analysis favors using prophylactic anticoagulation in covid-19 patients reduces all-cause mortality in comparison to therapeutic anticoagulation however the impact on mortality when compared with no anticoagulation was not significant.

see page 541

Original Articles

Efficacy of bupivacaine injection after pulsed radiofrequency ablation in the management of trigeminal facial pain. A prospective, randomized, and double-blind study

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

The alteration in the dose of medications post-procedure according to the study subjects.

Hilal et al assess the effect of bupivacaine application following pulsed radiofrequency (PRF) ablation on trigeminal facial pain of 73 patients with trigeminal facial pain refractory to conservative therapy. Group I subjects underwent PRF ablation procedure, followed by the injection of 1 ml of bupivacaine. Whereas, Group II underwent the same procedure followed by the injection of 1 ml of normal saline. The duration of pain relief in the 2 groups was comparable (5 months in group I vs. 6 months). The onset of pain relief in the patients of Group I was shorter than group II (0 days vs. 4.5 days). In situations involving patients who require rapid pain relief, bupivacaine injection following PRF ablation can be employed to provide immediate relief without subjecting the patients to the risks associated with major complications.

see page 551

Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Pfizer-BioNTech vaccine did not affect platelet counts. Platelets were quantified at day 0 (pre vaccine) and 14-22 days post-vaccination.

Algaissi et al evaluate the hematological parameters and thrombotic profiles of healthy individuals who received Pfizer-BioNTech (BNT162b2) vaccines in Saudi Arabia. A total of 40 patients 40 participants who were eligible for COVID-19 vaccination in Saudi Arabia (above 18 years old) at Jazan University Hospital. There were 38 men and 12 were women, with a mean age of 27 years. A total of 15% of the participants reported previous infection with SARS-CoV-2 and 3 patients had a history of diabetes mellitus and hypertension. Hematological parameters results in those vaccines showed no significant changes between the 2 timepoints, such as, day 0 (just before receiving vaccination) and 14 to 21 days post vaccination. Further, anti/PF4 antibodies were negative for all participants following vaccination. Data showed that the incidence of hematological abnormalities or induction of anti/PF4 antibodies following Pfizer-BioNTech (BNT162b2) vaccination is not common, which is consistent with several previous reports. However, larger studies with more participants evaluated at different timepoints following vaccination are warranted to exclude potential transient hematological abnormalities

see page 567

  • Copyright: © Saudi Medical Journal

This is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.

PreviousNext
Back to top

In this issue

Saudi Medical Journal: 43 (6)
Saudi Medical Journal
Vol. 43, Issue 6
1 Jun 2022
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In this issueSystematic ReviewOriginal Articles
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
In this issueSystematic ReviewOriginal Articles
Saudi Medical Journal Jun 2022, 43 (6) 539;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In this issueSystematic ReviewOriginal Articles
Saudi Medical Journal Jun 2022, 43 (6) 539;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • In this issueSystematic ReviewOriginal ArticlesCase Report
  • In this issueClinical GuidelinesOriginal Articles
Show more Abstract

Similar Articles

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire